[e-drug] Cost effectiveness and cost benefit analysis

E-DRUG: Cost effectiveness and cost benefit analysis
--------------------------------------
May I request for information on the following topics/issues:

1. How may cost effectiveness be assayed/measured (with particular reference on drug regimen)?

2. How may cost benefit analysis be assayed/measured (with particular reference on drug regimen)?

Dr.Abanum M.
Nigeria
mark_opollo@yahoo.com

[Moderator: I recommend to search the E-drug archive using 'cost effectiveness' and 'cost benefit' (pharmacoeconomic analysis) as search strings. There you will e.g. find reference to documents by countries that require such analysis for reimbursement of drugs. One often quoted is the Australian:
Australian guidelines (including economic analyses requirements) for
pharmaceutical industry submissions to our Pharmaceutical Benefits
Advisory Committee, can be found at:
http://www.health.gov.au/haf/docs/pharmpac/gusubpac.htm.\]

Cost effectiveness and cost benefit analysis (1)
------------------------------------

A two part article giving a brief introduction. Available freely from
National Prescribing Centre, UK (MeReC, www.npc.co.uk)

MeRec Briefing Issue no. 13. An introduction to health economics (part
1)
http://www.npc.co.uk/MeReC_Briefings/2000/briefing_no_13.pdf

Issue no. 14. An introduction to health economics (part 2). Applying
health economics
http://www.npc.co.uk/MeReC_Briefings/2000/briefing_no_14.pdf

Ms Kirsten Myhr, MScPharm, MPH
Head
RELIS Drug Info and ADR Monitoring Centre
Ulleval University Hospital
0407 OSLO, Norway
Tel: +47 23 01 64 11 Fax: +47 23 01 64 10
kirsten.myhr@relis.ulleval.no
myhr@online.no